KZIA Kazia Therapeutics
4,963
$0.271
$0.001
(0.37%)
| Watchers | 4,963 |
| 52-Wk Low | $0.1866 |
| 52-Wk High | $1.39 |
| Market Cap | $6.43M |
| Volume | 57,153.00 |
| 52-Wk High | $1.39 |
| 52-Wk Low | $0.1866 |
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSPR Newswire • 5 days ago
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN...
Share to Feed
Kazia Therapeutics Limited (NASDAQ:KZIA Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Kazia announces presentation of new data at AACR Annual Meeting Kazia announces presentation of new data at AACR Annual Meeting PR Newswire SYDNEY, March 13, 2024 SYDNEY, March 13, 2024 /PRNewswire...
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint PR Newswire...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS PR Newswire SYDNEY, Jan. 18, 2024 SYDNEY, Jan. 18, 2024 /PRNewswire/ -- Kazia...